Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU
Michimich.com/10294587

MIYUN, China - Michimich -- Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regulations of the European Medicines Agency.

Certificate information:

• Company name: Beijing Beilu pharmaceutical Co., Ltd.
• Manufacturing address: No.3 Shuiyuan West Road, Miyun District, Beijing, China
• Registration number: RVG 132878
• Drug name: Iohexol injection 350mg(I)/ml
• Issuing authority: Netherlands Medicines Evaluation Board (MEB)

The successful registration of Iohexol Injection in Netherland indicates that the product has undergone rigorous scientific evaluation by EMA, confirming its compliance with EU Good Manufacturing Practice (GMP), quality, safety and efficacy standards. This authorization enables commercial distribution in EU-approved countries. It creates conditions for speeding up the Mutual recognition procedures(MRP) among EU countries such as Germany, France, Italy and others as well. This will help Beilu Pharmaceutical further promote the expansion of its overseas market and enhance the international market competitiveness of its contrast agent products, which is expected to have a positive impact on the company's operations in the future.

More on Michimich.com

• Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
• Roofman USA Highlights the Importance of Choosing the Right Roofing Materials for Midwest Climates
• Boondocking Magazine Releases Fall 2026 Issue in Free Digital and Premium Print Formats
• Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
• HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory

Contact Information:
Beijing Beilu Pharmaceutical Co., Ltd.
https://www.beilupharma.com/
yanglm@beilupharma.com